{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:11:49Z","timestamp":1795011109618,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004690","name":"minist\u00e8re de la sant\u00e9","doi-asserted-by":"crossref","award":["STIC 2012 N\u00b0 2-12-0006"],"award-info":[{"award-number":["STIC 2012 N\u00b0 2-12-0006"]}],"id":[{"id":"10.13039\/501100004690","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anemia is a significant problem in patients on ICU. Its commonest cause, iron deficiency (ID), is difficult to diagnose in the context of inflammation. Hepcidin is a new marker of ID. We aimed to assess whether hepcidin levels would accurately guide treatment of ID in critically ill anemic patients after a prolonged ICU stay and affect the post-ICU outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a controlled, single-blinded, multicenter study, anemic (WHO definition) critically ill patients with an ICU stay\u2009\u2265\u20095\u00a0days were randomized when discharge was expected to either intervention by hepcidin treatment protocol or control. In the intervention arm, patients were treated with intravenous iron (1\u00a0g of ferric carboxymaltose) when hepcidin was\u2009&lt;\u200920\u00a0\u03bcg\/l and with intravenous iron and erythropoietin for 20\u2009\u2264\u2009hepcidin\u2009&lt;\u200941\u00a0\u03bcg\/l. Control patients were treated according to standard care (hepcidin quantification remained blinded). Primary endpoint was the number of days spent in hospital 90\u00a0days after ICU discharge (post-ICU LOS). Secondary endpoints were day 15 anemia, day 30 fatigue, day 90 mortality and 1-year survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 405 randomized patients, 399 were analyzed (201 in intervention and 198 in control arm). A total of 220 patients (55%) had ID at discharge (i.e., a hepcidin\u2009&lt;\u200941\u00a0\u03bcg\/l). Primary endpoint was not different (medians (IQR) post-ICU LOS 33(13;90) vs. 33(11;90) days for intervention and control, respectively, median difference \u2212\u20091(\u2212\u20093;1) days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.78). D90 mortality was significantly lower in intervention arm (16(8%) vs 33(16.6%) deaths, absolute risk difference \u2212\u20098.7 (\u2212\u200915.1 to \u2212\u20092.3)%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008, OR 95% IC, 0.46, 0.22\u20130.94,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.035), and one-year survival was improved (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treatment of ID diagnosed according to hepcidin levels did not reduce the post-ICU LOS, but was associated with a significant reduction in D90 mortality and with improved 1-year survival in critically ill patients about to be discharged after a prolonged stay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:italic>Trial registration<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrial.gov\">www.clinicaltrial.gov<\/jats:ext-link>\n                      NCT02276690 (October 28, 2014; retrospectively registered)\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13054-020-03430-3","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T09:16:29Z","timestamp":1613553389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Impact of treating iron deficiency, diagnosed according to hepcidin quantification, on outcomes after a prolonged ICU stay compared to standard care: a multicenter, randomized, single-blinded trial"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2901-4628","authenticated-orcid":false,"given":"Sigismond","family":"Lasocki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Asfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Jaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Ferrandiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kerforne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Asehnoune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Montravers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Seguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katell","family":"Peoc\u2019h","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soizic","family":"Gergaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Nagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Hepcidane study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigismond","family":"Lasocki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Asfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Jaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Ferrandiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kerforne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Asehnoune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Montravers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Seguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katell","family":"Peoc\u2019h","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soizic","family":"Gergaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Nagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Beloncle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Mercat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Leger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Rineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Sargentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Geneve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Puy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Delaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Chanques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Roquilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Boisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dahyot-Fizelier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Mimoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Isslame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoann","family":"Launey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Barbaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"issue":"12","key":"3430_CR1","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1001\/jama.288.12.1499","volume":"288","author":"JL Vincent","year":"2002","unstructured":"Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, Meier-Hellmann A, Nollet G, Peres-Bota D. Anemia and blood transfusion in critically ill patients. JAMA. 2002;288(12):1499\u2013507.","journal-title":"JAMA"},{"issue":"1","key":"3430_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00134-005-2855-2","volume":"32","author":"TS Walsh","year":"2006","unstructured":"Walsh TS, Lee RJ, Maciver CR, Garrioch M, Mackirdy F, Binning AR, Cole S, McClelland DB. Anemia during and at discharge from intensive care: the impact of restrictive blood transfusion practice. Intensive Care Med. 2006;32(1):100\u20139.","journal-title":"Intensive Care Med"},{"issue":"1","key":"3430_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13054-018-2018-9","volume":"22","author":"JL Vincent","year":"2018","unstructured":"Vincent JL, Jaschinski U, Wittebole X, Lefrant JY, Jakob SM, Almekhlafi GA, Pellis T, Tripathy S, Rubatto Birri PN, Sakr Y, et al. Worldwide audit of blood transfusion practice in critically ill patients. Crit Care. 2018;22(1):102.","journal-title":"Crit Care"},{"issue":"3","key":"3430_CR4","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1097\/ALN.0b013e3182065c57","volume":"114","author":"S Lasocki","year":"2011","unstructured":"Lasocki S, Longrois D, Montravers P, Beaumont C. Hepcidin and anemia of the critically ill patient. Anesthesiology. 2011;114(3):688\u201394.","journal-title":"Anesthesiology"},{"issue":"6","key":"3430_CR5","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1007\/s00134-010-1794-8","volume":"36","author":"S Lasocki","year":"2010","unstructured":"Lasocki S, Baron G, Driss F, Westerman M, Puy H, Boutron I, Beaumont C, Montravers P. Diagnostic accuracy of serum hepcidin for iron deficiency in critically ill patients with anemia. Intensive Care Med. 2010;36(6):1044\u20138.","journal-title":"Intensive Care Med"},{"issue":"5","key":"3430_CR6","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1097\/ALN.0b013e3181d74f87","volume":"112","author":"R Fernandez","year":"2010","unstructured":"Fernandez R, Tubau I, Masip J, Munoz L, Roig I, Artigas A. Low reticulocyte hemoglobin content is associated with a higher blood transfusion rate in critically ill patients: a cohort study. Anesthesiology. 2010;112(5):1211\u20135.","journal-title":"Anesthesiology"},{"issue":"1","key":"3430_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1089\/sur.2008.043","volume":"10","author":"FM Pieracci","year":"2009","unstructured":"Pieracci FM, Henderson P, Rodney JR, Holena DN, Genisca A, Ip I, Benkert S, Hydo LJ, Eachempati SR, Shou J, et al. Randomized, double-blind, placebo-controlled trial of effects of enteral iron supplementation on anemia and risk of infection during surgical critical illness. Surg Infect (Larchmt). 2009;10(1):9\u201319.","journal-title":"Surg Infect (Larchmt)"},{"issue":"12","key":"3430_CR8","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1097\/00003246-199912000-00005","volume":"27","author":"N von Ahsen","year":"1999","unstructured":"von Ahsen N, Muller C, Serke S, Frei U, Eckardt KU. Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med. 1999;27(12):2630\u20139.","journal-title":"Crit Care Med"},{"issue":"5","key":"3430_CR9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/s13054-014-0542-9","volume":"18","author":"S Lasocki","year":"2014","unstructured":"Lasocki S, Chudeau N, Papet T, Tartiere D, Roquilly A, Carlier L, Mimoz O, Seguin P, Malledant Y, Asehnoune K, et al. Prevalence of iron deficiency on ICU discharge and its relation with fatigue: a multicenter prospective study. Crit Care. 2014;18(5):542.","journal-title":"Crit Care"},{"issue":"2S2","key":"3430_CR10","doi-asserted-by":"publisher","first-page":"676S","DOI":"10.1093\/jn\/131.2.676S","volume":"131","author":"JD Haas","year":"2001","unstructured":"Haas JD, Brownlie T. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr. 2001;131(2S2):676S-688S discussion 688S\u2013690S.","journal-title":"J Nutr"},{"issue":"25","key":"3430_CR11","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436\u201348.","journal-title":"N Engl J Med"},{"issue":"12","key":"3430_CR12","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1182\/blood-2011-04-346304","volume":"118","author":"PA Krayenbuehl","year":"2011","unstructured":"Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood. 2011;118(12):3222\u20137.","journal-title":"Blood"},{"issue":"5","key":"3430_CR13","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/bjh.12311","volume":"161","author":"DW Thomas","year":"2013","unstructured":"Thomas DW, Hinchliffe RF, Briggs C, Macdougall IC, Littlewood T, Cavill I. British Committee for Standards in H: Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol. 2013;161(5):639\u201348.","journal-title":"Br J Haematol"},{"issue":"2","key":"3430_CR14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/bjh.15067","volume":"184","author":"A Shah","year":"2019","unstructured":"Shah A, Wray K, James T, Shine B, Morovat R, Stanworth S, McKechnie S, Kirkbride R, Griffith DM, Walsh TS, et al. Serum hepcidin potentially identifies iron deficiency in survivors of critical illness at the time of hospital discharge. Br J Haematol. 2019;184(2):279\u201381.","journal-title":"Br J Haematol"},{"issue":"1","key":"3430_CR15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s13054-018-2253-0","volume":"22","author":"S Lasocki","year":"2018","unstructured":"Lasocki S, Lefebvre T, Mayeur C, Puy H, Mebazaa A, Gayat E. group F-Is: Iron deficiency diagnosed using hepcidin on critical care discharge is an independent risk factor for death and poor quality of life at one year: an observational prospective study on 1161 patients. Crit Care. 2018;22(1):314.","journal-title":"Crit Care"},{"issue":"6","key":"3430_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.accpm.2017.04.009","volume":"36","author":"S Lasocki","year":"2017","unstructured":"Lasocki S, Puy H, Mercier G, Lehmann S. Hepcidane study g: impact of iron deficiency diagnosis using hepcidin Mass Spectrometry dosage methods on hospital stay and costs after a prolonged ICU stay: study protocol for a multicentre, randomised, single-blinded medico-economic trial. Anaesth Crit Care Pain Med. 2017;36(6):391\u20136.","journal-title":"Anaesth Crit Care Pain Med"},{"key":"3430_CR17","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2014-1093","author":"T Lefebvre","year":"2015","unstructured":"Lefebvre T, Dessendier N, Houamel D, Ialy-Radio N, Kannengiesser C, Manceau H, Beaumont C, Nicolas G, Gouya L, Puy H, et al. LC-MS\/MS method for hepcidin-25 measurement in human and mouse serum: clinical and research implications in iron disorders. Clin Chem Lab Med. 2015. https:\/\/doi.org\/10.1515\/cclm-2014-1093.","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"3430_CR18","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1097\/CCM.0b013e31818103b9","volume":"36","author":"S Lasocki","year":"2008","unstructured":"Lasocki S, Millot S, Andrieu V, Letteron P, Pilard N, Muzeau F, Thibaudeau O, Montravers P, Beaumont C. Phlebotomies or erythropoietin injections allow mobilization of iron stores in a mouse model mimicking intensive care anemia. Crit Care Med. 2008;36(8):2388\u201394.","journal-title":"Crit Care Med"},{"issue":"1","key":"3430_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1046\/j.1365-2354.2003.00295.x","volume":"12","author":"S Gentile","year":"2003","unstructured":"Gentile S, Delaroziere JC, Favre F, Sambuc R, San Marco JL. Validation of the French \u201cmultidimensional fatigue inventory\u201d (MFI 20). Eur J Cancer Care (Engl). 2003;12(1):58\u201364.","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"398","key":"3430_CR20","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1080\/01621459.1987.10478478","volume":"82","author":"GE Noether","year":"1987","unstructured":"Noether GE. Sample size determination for some common nonparametric tests. J Am Stat Assoc. 1987;82(398):645\u20137.","journal-title":"J Am Stat Assoc"},{"key":"3430_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/archinte.1962.03620230109016","volume":"110","author":"GG Jackson","year":"1962","unstructured":"Jackson GG, Arana-Sialer JA, Andersen B, Grieble HG, Mc CW. Profiles of pyelonephritis. Arch Intern Med. 1962;110:63\u201375.","journal-title":"Arch Intern Med"},{"issue":"11","key":"3430_CR22","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s00134-016-4465-6","volume":"42","author":"I Investigators","year":"2016","unstructured":"Investigators I, Litton E, Baker S, Erber WN, Farmer S, Ferrier J, French C, Gummer J, Hawkins D, Higgins A, et al. Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial: a randomized trial of IV iron in critical illness. Intensive Care Med. 2016;42(11):1715\u201322.","journal-title":"Intensive Care Med"},{"issue":"9","key":"3430_CR23","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1097\/CCM.0000000000000408","volume":"42","author":"FM Pieracci","year":"2014","unstructured":"Pieracci FM, Stovall RT, Jaouen B, Rodil M, Cappa A, Burlew CC, Holena DN, Maier R, Berry S, Jurkovich J, et al. A multicenter, randomized clinical trial of IV iron supplementation for anemia of traumatic critical illness*. Crit Care Med. 2014;42(9):2048\u201357.","journal-title":"Crit Care Med"},{"key":"3430_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jcrc.2018.11.005","volume":"49","author":"A Shah","year":"2019","unstructured":"Shah A, Fisher SA, Wong H, Roy NB, McKechnie S, Doree C, Litton E, Stanworth SJ. Safety and efficacy of iron therapy on reducing red blood cell transfusion requirements and treating anaemia in critically ill adults: a systematic review with meta-analysis and trial sequential analysis. J Crit Care. 2019;49:162\u201371.","journal-title":"J Crit Care"},{"issue":"3","key":"3430_CR25","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/CCM.0000000000001420","volume":"44","author":"S Lasocki","year":"2016","unstructured":"Lasocki S, Piednoir P, Couffignal C, Rineau E, Dufour G, Lefebvre T, Puy H, Duval X, Driss F, Schilte C. Does IV iron induce plasma oxidative stress in critically ill patients? a comparison with healthy volunteers. Crit Care Med. 2016;44(3):521\u201330.","journal-title":"Crit Care Med"},{"issue":"3","key":"3430_CR26","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1016\/S2352-3026(14)00025-8","volume":"1","author":"MN Garcia-Casal","year":"2014","unstructured":"Garcia-Casal MN, Pena-Rosas JP, Pasricha SR. Rethinking ferritin cutoffs for iron deficiency and overload. Lancet Haematol. 2014;1(3):e92-94.","journal-title":"Lancet Haematol"},{"issue":"6","key":"3430_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.arcmed.2018.12.005","volume":"49","author":"MN Garcia-Casal","year":"2018","unstructured":"Garcia-Casal MN, Pasricha SR, Martinez RX, Lopez-Perez L, Pena-Rosas JP. Are current serum and plasma ferritin cut-offs for iron deficiency and overload accurate and reflecting iron status? A systematic review. Arch Med Res. 2018;49(6):405\u201317.","journal-title":"Arch Med Res"},{"issue":"7","key":"3430_CR28","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1373\/clinchem.2016.256768","volume":"62","author":"LN van der Vorm","year":"2016","unstructured":"van der Vorm LN, Hendriks JC, Laarakkers CM, Klaver S, Armitage AE, Bamberg A, Geurts-Moespot AJ, Girelli D, Herkert M, Itkonen O, et al. Toward worldwide hepcidin assay harmonization: identification of a commutable secondary reference material. Clin Chem. 2016;62(7):993\u20131001.","journal-title":"Clin Chem"},{"issue":"10","key":"3430_CR29","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/ajh.23289","volume":"87","author":"JJ Kroot","year":"2012","unstructured":"Kroot JJ, van Herwaarden AE, Tjalsma H, Jansen RT, Hendriks JC, Swinkels DW. Second round robin for plasma hepcidin methods: first steps toward harmonization. Am J Hematol. 2012;87(10):977\u201383.","journal-title":"Am J Hematol"},{"issue":"6","key":"3430_CR30","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1515\/cclm-2018-0783","volume":"57","author":"LE Diepeveen","year":"2019","unstructured":"Diepeveen LE, Laarakkers CMM, Martos G, Pawlak ME, Uguz FF, Verberne K, van Swelm RPL, Klaver S, de Haan AFJ, Pitts KR, et al. Provisional standardization of hepcidin assays: creating a traceability chain with a primary reference material, candidate reference method and a commutable secondary reference material. Clin Chem Lab Med. 2019;57(6):864\u201372.","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"3430_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13054-017-1922-8","volume":"22","author":"E Gayat","year":"2018","unstructured":"Gayat E, Cariou A, Deye N, Vieillard-Baron A, Jaber S, Damoisel C, Lu Q, Monnet X, Rennuit I, Azoulay E, et al. Determinants of long-term outcome in ICU survivors: results from the FROG-ICU study. Crit Care. 2018;22(1):8.","journal-title":"Crit Care"},{"issue":"5","key":"3430_CR32","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/jalm\/jfaa038","volume":"5","author":"P Gutschow","year":"2020","unstructured":"Gutschow P, Han H, Olbina G, Westerman K, Nemeth E, Ganz T, Copeland K, Westerman M, Ostland V. Clinical immunoassay for human hepcidin predicts iron deficiency in first-time blood donors. J Appl Lab Med. 2020;5(5):943\u201353.","journal-title":"J Appl Lab Med"},{"issue":"5","key":"3430_CR33","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa1810742","volume":"380","author":"IC Macdougall","year":"2019","unstructured":"Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Tomson CRV, Wheeler DC, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019;380(5):447\u201358.","journal-title":"N Engl J Med"},{"issue":"1","key":"3430_CR34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/ejhf.823","volume":"20","author":"SD Anker","year":"2018","unstructured":"Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F, Luscher TF, Arutyunov GP, Motro M, Mori C, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018;20(1):125\u201333.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"3430_CR35","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1007\/s00134-019-05686-y","volume":"45","author":"E Litton","year":"2019","unstructured":"Litton E, Latham P, Inman J, Luo J, Allan P. Safety and efficacy of erythropoiesis-stimulating agents in critically ill patients admitted to the intensive care unit: a systematic review and meta-analysis. Intensive Care Med. 2019;45(9):1190\u20139.","journal-title":"Intensive Care Med"},{"key":"3430_CR36","first-page":"CD010969","volume":"8","author":"B Mesgarpour","year":"2017","unstructured":"Mesgarpour B, Heidinger BH, Roth D, Schmitz S, Walsh CD, Herkner H. Harms of off-label erythropoiesis-stimulating agents for critically ill people. Cochrane Database Syst Rev . 2017;8:CD010969.","journal-title":"Cochrane Database Syst Rev"},{"key":"3430_CR37","doi-asserted-by":"crossref","unstructured":"Lasocki S, Pene F, Ait-Oufella H, Aubron C, Ausset S, Buffet P, Huet O, Launey Y, Legrand M, Lescot T et al: Management and prevention of anemia (acute bleeding excluded) in adult critical care patients. Anaesth Crit Care Pain Med 2020.","DOI":"10.1186\/s13613-020-00711-6"},{"key":"3430_CR38","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1007\/s00134-020-06175-3","volume":"46","author":"S Lasocki","year":"2020","unstructured":"Lasocki S, Kimmoun A, Chanques G, Velly L, Pene F. Treating critically ill anaemic patients with erythropoietin: why not? Intensive Care Med. 2020;46:1794\u20135.","journal-title":"Intensive Care Med"},{"issue":"6","key":"3430_CR39","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.accpm.2018.10.013","volume":"37","author":"E Toulouse","year":"2018","unstructured":"Toulouse E, Masseguin C, Lafont B, McGurk G, Harbonn A, Roberts JA, Granier S, Dupeyron A, Bazin JE. French legal approach to clinical research. Anaesth Crit Care Pain Med. 2018;37(6):607\u201314.","journal-title":"Anaesth Crit Care Pain Med"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-020-03430-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-020-03430-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-020-03430-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T11:49:12Z","timestamp":1622548152000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-020-03430-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3430"],"URL":"https:\/\/doi.org\/10.1186\/s13054-020-03430-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-73447\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-73447\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-73447\/v1","asserted-by":"object"}]},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"6 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following French law [\n                      \n                      ], the study protocol has been approved by an IRB (Comit\u00e9 de Protection des Personnes (CPP) Sud M\u00e9diterran\u00e9e IV, REF 13 07 05, protocol No 2013-A00964-41) and by the CNIL (Commission Nationale de l\u2019Informatique et des Libert\u00e9s, MR-001 of May 7, 2012 (No 1585321 v0)). The protocol has been registered by the competent authority (ANSM\u2014Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9) under the reference number 2013-192 and on\n                      \n                      under the reference NCT02276690 (October 28, 2014). A signed informed consent was obtained from each patient (or from his\/her next of kin if the patient was unable to consent).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Sigismond Lasocki has received speaker honoraria from VIFOR Pharma, MASIMO, LFB and fee as member of advisory board and\/or steering committee from VIFOR Pharma and Pfizer.. SLa is the coordinator of a multicenter randomized controlled trial on iron and tranexamic acid in hip fractured patients (HIFIT study, NCT02972294), for which PHARMACOSMOS gives iron for free. Philippe Seguin has received fee from LFB. None of the other authors have a competing interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}